ClinicalTrials.gg

Program

CDK4 Inhibitor BGB-43395

Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis, led by BeOne Medicines.

Furthest: phase 3, since Mar 20, 20264 company-led studies, 2 open or runningNext primary completion: Nov 22, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines42 open or runningphase 3since Mar 20, 2026Feb 2, 2024Nov 22, 2026phase 1 · NCT07820891

Also a collaborator on its studies: Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2024First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06253195 · 33 enrolled · China
  2. Dec 31, 2024Phase 1 study in Healthy VolunteersNCT06761898 · 51 enrolled · United States
  3. Mar 20, 2026Phase 3 study in HR+/HER2- Breast CancerPhase 3 reachedNCT07492641 · 1,056 planned · United States, Australia, Brazil and more
  4. Sep 10, 2026Phase 1 study in Healthy Adult ParticipantsNCT07820891 · 24 planned · United States

Ahead

  1. Nov 22, 2026Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07820891
  2. Apr 2029Primary completion: phase 3 study in HR+/HER2- Breast CancerNCT07492641

TargetBeta

CDK4 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule

Other programs on CDK4

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
atirmociclibPfizerphase 317
culmerciclibSino Biopharmaceuticalphase 311
HRS-6209Jiangsu HengRui Medicinephase 37
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
TSL2109ruleChina Resources Pharmaceutical Groupphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07820891Healthy Adult Participants · United States1RecruitingNov 22, 202624
NCT07492641HR+/HER2- Breast Cancer · United States, Australia, Brazil and more3RecruitingApr 20291,056
NCT06761898Healthy Volunteers · United States1CompletedMay 20, 202551
NCT06253195Neoplasm Metastasis · China1CompletedApr 23, 202633

How it is read

Names in the registry

  • “BGB-43395”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.